Drug Trial Radar · NCT05787418
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
918
Actual
Start
Mar 31, 2023
Primary completion
Mar 27, 2024
Study completion Apr 17, 2024
Sponsor
- Lead sponsor
- Huahui HealthIndustry
- Sponsor type
- Industry
- First posted
- Mar 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.
Conditions
- COVID-19
Interventions
HH-120 Nasal SprayDrug
HH-120 nasal spray 8 times per day for 7 consecutive days
PlaceboDrug
Placebo 8 times per day for 7 consecutive days
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of symptomatic SARS-CoV-2 infectionTime frame: Up to 7 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital, Capital Medical University
Beijing, China
Huashan Hospital of Fudan University
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.